neck cancer

Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of...

Galera Therapeutics Inc (NASDAQ: GRTX) stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC)...

Hookipa Pharma Inc (NASDAQ: HOOK) has entered into a clinical collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The collaboration will evaluate the combination of HB-200 and Keytruda (pembrolizumab) as first-line treatment of advanced head and neck...

The FDA has granted Breakthrough Therapy Designation (BTD) to Shanghai Junshi Biosciences Co Ltd - Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab for recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck. The...

Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints of the trial.  The trial assessed Opdivo plus Yervoy combination to Extreme regimen (cetuximab...

Galectin Therapeutics Inc (NASDAQ: GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with metastatic melanoma and head &...

Immutep Limited (NASDAQ: IMMP) has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recruitment for the trial will begin in Q3 of 2021. It will evaluate the Company's...

CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In the intent to treat patients, the study showed a statistically significant overall...

Vaccinex Inc (NASDAQ: VCNX) has activated first clinical sites to screen and enroll patients in its Phase 1/2 study evaluating pepinemab as a single agent in Alzheimer's disease (AD) and in its phase 2 study in combination with Merck & Co Inc's (NYSE: MRK)...

Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients in a small Phase 1 trial. NBTXR3 consists of crystalline nanoparticles that are delivered...

BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastatic nasopharyngeal cancer, a rare type of head and neck cancer. The trial...

Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)....